Literature DB >> 7492924

Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11.

S Sonis1, A Muska, J O'Brien, A Van Vugt, P Langer-Safer, J Keith.   

Abstract

Ninety-five young, male Golden Syrian hamsters were randomly divided into five equally sized groups. One group served as a placebo control while the animals in the others received one of four doses of interleukin-eleven (IL-11) twice daily given by subcutaneous injection beginning on the first day of chemotherapy (day 0) and continuing to day 14. Mucositis was induced with 5-fluorouracil using a standard regimen of 60 mg/kg, intraperitoneally on days 0 and 2 followed by superficial mucosal irritation on day 4. Animals were evaluated daily beginning on day 6. Mucositis was assessed using a standardised technique in which randomly numbered daily mucosal photographs were scored by three blinded independent observers at the conclusion of the experiment. IL-11 favourably affected the frequency, severity and duration of mucositis. This phenomenon appeared to be dose dependent. Hamsters receiving 30 and 100 micrograms per day of IL-11 demonstrated significantly (P < 0.05) lower mucositis scores than did either the control or animals receiving 3 or 10 micrograms per day, although the latter had marginal beneficial effects. Additionally, survival was significantly better for hamsters receiving higher doses of IL-11 (85%) compared to the placebo control (46%). IL-11 administration also favourably affected weight loss. While stimulation of platelet production was noted in animals receiving IL-11, a lack of difference in bone marrow cellularity between test and control animals suggests that the mechanism by which IL-11 modifies mucositis is mediated at the epithelial or connective tissue level rather than through the marrow. The kinetics of IL-11 alteration of mucositis induction supports such a hypothesis. Further investigation is currently underway to establish a definitive mechanism by which IL-11 protects the oral mucosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492924     DOI: 10.1016/0964-1955(95)00015-a

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  6 in total

1.  Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation.

Authors:  R L Peterson; M M Bozza; A J Dorner
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

2.  A milk growth factor extract reduces chemotherapeutic drug toxicity in epithelial cells in vitro.

Authors:  V L Taylor; C Goddard; L C Read
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-05       Impact factor: 2.416

Review 3.  Chemotherapy-induced oral mucositis. Prevention and management.

Authors:  J J Knox; A L Puodziunas; R Feld
Journal:  Drugs Aging       Date:  2000-10       Impact factor: 3.923

4.  Functional characterization of W147A: a high-affinity interleukin-11 antagonist.

Authors:  Nicholas Underhill-Day; Lisa A McGovern; Natalia Karpovich; Helen J Mardon; Victoria A Barton; John K Heath
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

5.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  G R Hill; K R Cooke; T Teshima; J M Crawford; J C Keith; Y S Brinson; D Bungard; J L Ferrara
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

6.  Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.

Authors:  Masooma Sultani; Andrea M Stringer; Joanne M Bowen; Rachel J Gibson
Journal:  Chemother Res Pract       Date:  2012-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.